Filtered news list test

Filtered news list testing

Guerbet receives EMA acceptance of Elucirem™ as the Brand Name for Gadopiclenol.

Read the article

Q1 2022 sales

Read the article

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel

Read the article

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA

Read the article

2021 annual results

Read the article

Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization

Read the article

2021 revenue

Read the article

Webinar: Liver focal lesions: where do we stand with detection and interest of AI?

Guerbet announces appointment of Jared Houk as Commercial Vice President for North America

Read the article

Indice vert CAHPP : Guerbet obtient le label A++

Gaïa-Index 2021: Guerbet consolidates its position as a leader in the “Healthcare” category

Read the article

3
4
5
6
Current page7
8
9
10
11

Single report testing

.pdf

test report fabien V 09-07

Separator

Filtered images

David Hale, CEO Of Guerbet ©Eric LARRAYADIEU

Life At Work At Guerbet HQ ©Eric LARRAYADIEU

Artificial Intelligence And Physician

CT Procedure With Optivantage Multi Use 01

C TACE Procedure With Injection And Emulsion

Guerbet Fill And Finish Site At Aulnay © Patrick Allard REA

Life At Work At Guerbet HQ (2) ©Eric LARRAYADIEU

Guerbet Fill And Finish Site At Aulnay (2) © Patrick Allard REA

Manual news 1

subtitle

item 1 text

item 1 title

Link text

Manual news 2

item 1 text

item 1 title

link

item 2 title

Teest

Discover the latest news of Guerbet

U.S. Food and Drug Administration (FDA) grants Breakthrough Device status to the Guerbet innovation: LIPIOJOINT

Read the press release

2024 revenue

Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow^®, innovative solution dedicated to oncology imaging

Read the press release

UNIK: Diagnostic Imaging Interconnected Solutions

UNIK: Diagnostic Imaging Interconnected Solutions

UNIK: Diagnostic Imaging Interconnected Solutions

Interventional Imaging Solutions

Women’s Health

Filtered news list testing

Guerbet receives EMA acceptance of Elucirem™ as the Brand Name for Gadopiclenol.

Q1 2022 sales

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA

2021 annual results

Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization

2021 revenue

Guerbet announces appointment of Jared Houk as Commercial Vice President for North America

Gaïa-Index 2021: Guerbet consolidates its position as a leader in the “Healthcare” category

List of Reports

12/31/2012 - Registration document 2012

06/30/2012 - Half-yearly financial report 2012

12/31/2011 - Registration document

06/30/2011 - Half-yearly financial report 2011

12/31/2010 - Registration document

06/30/2010 - Half-yearly financial report 2010

Single report testing

test report fabien V 09-07

Separator

Filtered images

Manual news 1

item 1 title

Manual news 2

item 1 title

item 2 title

Discover the latest news of Guerbet

U.S. Food and Drug Administration (FDA) grants Breakthrough Device status to the Guerbet innovation: LIPIOJOINT

2024 revenue

Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow^®, innovative solution dedicated to oncology imaging

UNIK: Diagnostic Imaging Interconnected Solutions

UNIK: Diagnostic Imaging Interconnected Solutions

UNIK: Diagnostic Imaging Interconnected Solutions

Interventional Imaging Solutions

Women’s Health

Filtered news list testing

Guerbet receives EMA acceptance of Elucirem™ as the Brand Name for Gadopiclenol.

Q1 2022 sales

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA

2021 annual results

Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization

2021 revenue

Guerbet announces appointment of Jared Houk as Commercial Vice President for North America

Gaïa-Index 2021: Guerbet consolidates its position as a leader in the “Healthcare” category

List of Reports

12/31/2012 - Registration document 2012

06/30/2012 - Half-yearly financial report 2012

12/31/2011 - Registration document

06/30/2011 - Half-yearly financial report 2011

12/31/2010 - Registration document

06/30/2010 - Half-yearly financial report 2010

Single report testing

test report fabien V 09-07

Separator

Filtered images

Manual news 1

item 1 title

Manual news 2

item 1 title

item 2 title

Discover the latest news of Guerbet

U.S. Food and Drug Administration (FDA) grants Breakthrough Device status to the Guerbet innovation: LIPIOJOINT

2024 revenue

Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow®, innovative solution dedicated to oncology imaging

Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow^®, innovative solution dedicated to oncology imaging